BioRestorative Therapies (BRTX) Registration Filing summary

Management team and governance

• President, CEO, and Chairman is Lance Alstodt; other key officers include Francisco Silva (VP, R&D), Robert E. Kristal (CFO), Nickolay Kukekov, Patrick F. Williams, and David Rosa as directors.

• Executive and incentive stock option agreements are in place for senior management, with recent awards dated through February 2025.

Offering details and pricing

• Placement involves registered shares of common stock or pre-funded warrants, and warrants to purchase common stock.

• Terms of the placement, including pricing, are to be mutually agreed upon by the company, placement agent, and purchasers.

• Placement agent receives a 7% cash fee on gross proceeds and warrants equal to 7% of the total shares and pre-funded warrants sold, exercisable at 125% of the public offering price.

• Placement agent may be reimbursed up to $100,000 for expenses upon closing.

Underwriters and syndicate

• Rodman & Renshaw LLC serves as exclusive placement agent on a reasonable best efforts basis.

• Placement agent may retain sub-agents or selected dealers.

• Placement agent is a FINRA member and registered broker/dealer.